Biogen Idec (BIIB) Said Baminercept Trial Failed To Meet Primary Endpoint
Tweet Send to a Friend
Biogen Idec (NASDAQ: BIIB) announced today that its Phase II trial of baminercept in rheumatoid arthritis (RA) patients who have ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
